Search

Author/Creator Utikal, Jochen

1. 391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors. (10th December 2020)

Authors:
Bechter, Oliver; Utikal, Jochen; Baurain, Jean-Francois; Massard, Christophe; Sahin, Ugur; Derhovanessian, Evelyna; Ozoux, Marie-Laure; Marpadga, Rahul; Imedio, Esteban-Rodrigo; Acquavella, Nicolas; Loquai, Carmen
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A universal anti‐cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. Issue 4 (5th December 2018)

Authors:
Sharbi‐Yunger, Adi; Grees, Mareike; Cafri, Gal; Bassan, David; Eichmüller, Stefan B.; Tzehoval, Esther; Utikal, Jochen; Umansky, Viktor; Eisenbach, Lea
Journal:
International journal of cancer
Issue:
Volume 144:Issue 4(2019)
Page Start:
909
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Issue 10358 (1st October 2022)

Authors:
Livingstone, Elisabeth; Zimmer, Lisa; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas K; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kiecker, Felix; Dippel, Edgar; Roesch, Alexander; Ziemer, Mirj...
Journal:
Lancet
Issue:
Volume 400:Issue 10358(2022)
Page Start:
1117
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021)

Authors:
Eggermont, Alexander M M; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A; Rutkowski, Piotr; Schadendorf, Dirk;...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 5(2021)
Page Start:
643
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021)

Authors:
Bottomley, Andrew; Coens, Corneel; Mierzynska, Justyna; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Puig, Susana; Ascierto, Paolo A; Larkin, James; Loriga...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 5(2021)
Page Start:
655
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗